Gritstone Oncology Advances into Phase 2 Expansion Cohorts for its Personalized Neoantigen Therapy
EMERYVILLE, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that it has begun dosing patients in the Phase 2 expansion cohorts of the Phase 1/2 clinical studies for GRANITE and SLATE, its neoantigen-based immunotherapies. “We are excited to advance the highest doses of GRANITE and SLATE tested in the